Skip to main content
. 2023 Jun 2;64:102762. doi: 10.1016/j.redox.2023.102762

Fig. 1.

Fig. 1

OxLDL markers in PD and HD patients versus control group. Cholesteryl ester-OOH levels are significantly higher in PD versus HD patients and control group (1.59 ± 1.01 vs 0.95 ± 0.76 and 0.83 ± 0.47), as are also free cholesterol-OOH levels (0.74 ± 0.90 vs 0.40 ± 0.35 and 0.16 ± 0.10), and triglyceride-OOH levels (7.17 ± 5.64 vs 1.52 ± 1.04 and 1.03 ± 0.74), respectively. Phospholipid-OOH levels are significantly higher in PD patients versus control (0.22 ± 0.24 vs 0.12 ± 0.06) and higher but not significantly in PD versus HD patients (0.18 ± 0.19). All these markers are expressed as nmoles cum-OOH equivalent/mg apoB100. ApoB100-MDA levels (expressed as pmoles MDA/mg apoB100) are higher, but not significantly, in PD versus HD patients and control (0.22 ± 0.24 vs 0.18 ± 0.19 and 0.12 ± 0.06). ApoB100-DiTyr levels (expressed as pmoles DiTyr/mg apoB100) are higher, but not significantly, in PD patients versus control (9.06 ± 5.97 vs 8.79 ± 2.78) and lower, but not significantly in PD versus HD patients (10.84 ± 5.40). LDL carotenoid levels (expressed as nmoles carotenoids/mg apoB100) are significantly higher in PD patients versus control (0.82 ± 0.55 vs 0.32 ± 0.33). OxLDL markers' average level comparisons are shown in a numerical Y-axis (with units ± standard deviation presented as error bars).